"Given the uncertainty regarding timing of a market recovery, we believe that this transaction offers the best opportunity at this time for continued growth and for our company to gain access to the public capital markets."

— David Martin, president/CEO of Cardiovascular Systems, discussing his company's plans to merge with another, "Cardiovascular Systems plans all-stock deal with Replidyne."

No Comments